CAR-T Meeting 2022 | Outcomes and management of patients who develop COVID-19 after CD19-targeted CAR-T therapy
Stephan Mielke, MD, PhD, Karolinska Institute, Solna, Sweden, discusses the outcomes and management strategies for patients with B-cell malignancies who are infected with COVID-19 after receiving CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy. COVID-19 infection represents a significant challenge for these patients as treatment with CD19-targeted CAR-T therapy often results in B-cell aplasia, which leads to suboptimal serological responses to COVID-19 vaccination. It is currently unknown whether frequent vaccination can help to overcome this challenge. In addition, it has been shown that patients infected with COVID-19 after CD19-targeted CAR-T therapy experience high mortality. It is thus important for these patients to respect social distancing measures and receive prophylactic infusions of monoclonal antibodies. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Celgene/BMS, Novartis, DNA Prime SA: Speakers bureau (via institution)
Gilead/KITE: Other: Travel support, Expert panel (via institution)
Miltenyi, Immunicum: Other: Data safety monitoring board (via institution)
